Immunotherapy combo shows promise for Hard-to-Treat ovarian cancer
NCT ID NCT03026062
First seen Jun 26, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after the other to see which approach works better. The goal was to delay cancer growth by boosting the immune system's ability to attack tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab and tremelimumab (immunotherapy drugs)
- What this could lead to
- If successful, this could point toward a new treatment option for women with ovarian cancer that has stopped responding to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial (100 participants) with no control group, so results may not lead to a proven therapy. Immunotherapy can cause serious side effects like inflammation of organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Immune cells retrained to hunt ovarian cancer in new trial
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- Cancer drug combo tested for rare gene mutation – but trial stopped early